ARQT Arcutis Biotherapeutics Inc

Price (delayed)

$10.23

Market cap

$624.88M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.66

Enterprise value

$772.55M

Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent ...

Highlights
Arcutis Biotherapeutics's gross margin has increased by 26% QoQ
ARQT's EPS is down by 35% YoY but it is up by 4.1% QoQ
Arcutis Biotherapeutics's debt has surged by 161% YoY
Arcutis Biotherapeutics's net income has shrunk by 51% YoY

Key stats

What are the main financial stats of ARQT
Market
Shares outstanding
61.08M
Market cap
$624.88M
Enterprise value
$772.55M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.97
Price to sales (P/S)
152.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
209.59
Earnings
Revenue
$3.69M
EBIT
-$295.81M
EBITDA
-$294.55M
Free cash flow
-$258.05M
Per share
EPS
-$5.66
Free cash flow per share
-$4.69
Book value per share
$3.44
Revenue per share
$0.07
TBVPS
$8.03
Balance sheet
Total assets
$449.27M
Total liabilities
$239.69M
Debt
$202.54M
Equity
$209.58M
Working capital
$399.6M
Liquidity
Debt to equity
0.97
Current ratio
11.57
Quick ratio
11.09
Net debt/EBITDA
-0.5
Margins
EBITDA margin
-7,991.1%
Gross margin
79.5%
Net margin
-8,449.8%
Operating margin
-8,183%
Efficiency
Return on assets
-76.8%
Return on equity
-134%
Return on invested capital
-67.2%
Return on capital employed
-71.9%
Return on sales
-8,025.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARQT stock price

How has the Arcutis Biotherapeutics stock price performed over time
Intraday
-5.28%
1 week
-7.75%
1 month
-34.67%
1 year
-42.17%
YTD
-30.88%
QTD
-30.88%

Financial performance

How have Arcutis Biotherapeutics's revenue and profit performed over time
Revenue
$3.69M
Gross profit
$2.93M
Operating income
-$301.63M
Net income
-$311.46M
Gross margin
79.5%
Net margin
-8,449.8%
The operating margin has soared by 81% from the previous quarter
Arcutis Biotherapeutics's net margin has surged by 80% QoQ
Arcutis Biotherapeutics's net income has shrunk by 51% YoY
The company's operating income fell by 46% YoY

Growth

What is Arcutis Biotherapeutics's growth rate over time

Valuation

What is Arcutis Biotherapeutics stock price valuation
P/E
N/A
P/B
2.97
P/S
152.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
209.59
ARQT's EPS is down by 35% YoY but it is up by 4.1% QoQ
The stock's price to book (P/B) is 31% less than its last 4 quarters average of 4.3
Arcutis Biotherapeutics's equity has decreased by 30% YoY and by 23% QoQ

Efficiency

How efficient is Arcutis Biotherapeutics business performance
The ROE has plunged by 148% YoY and by 10% from the previous quarter
ARQT's ROS has soared by 81% QoQ
ARQT's return on assets has dropped by 58% year-on-year but it is up by 2.3% since the previous quarter
The company's return on invested capital rose by 13% QoQ and by 4% YoY

Dividends

What is ARQT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARQT.

Financial health

How did Arcutis Biotherapeutics financials performed over time
ARQT's total assets is 87% greater than its total liabilities
The total liabilities has soared by 117% YoY
Arcutis Biotherapeutics's quick ratio has decreased by 14% QoQ and by 4.9% YoY
Arcutis Biotherapeutics's debt is 3.4% lower than its equity
Arcutis Biotherapeutics's debt has surged by 161% YoY
ARQT's debt to equity is up by 31% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.